SCHEMBL654268

SCHEMBL654268

O=c1c2[c]cccc2oc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 8/20 0.63
KDM4E B2RXH2 3/20 0.63
ALDH1A1 P00352 2/20 0.63
CYP3A4 P08684 2/20 0.63
GLA P06280 1/20 0.63
MAPT P10636 1/20 0.63
HPGD P15428 1/20 0.63
PGAM1 P18669 1/20 0.63
CASP1 P29466 1/20 0.63
CASP7 P55210 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
HSD17B10 Q99714 1/20 0.63
NPC1 O15118 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 3/20 0.44
TTR P02766 2/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5099 0.84 MAOA (0.48) MAOAKDM4EALDH1A1CYP3A4GLA
SCHEMBL11172224 0.79 KDM4E (0.47) MAOAKDM4EALDH1A1CYP3A4GLA
SCHEMBL3368451 0.79 MAOA (0.61) MAOAKDM4EALDH1A1CYP3A4GLA
Xanthone SCHEMBL2354794 0.79 MAOA (1.00) MAOAKDM4EALDH1A1CYP3A4GLA
Xanthone SCHEMBL29358061 0.79 MAOA (1.00) MAOAKDM4EALDH1A1CYP3A4GLA
Xanthone SCHEMBL29398266 0.79 MAOA (1.00) MAOAKDM4EALDH1A1CYP3A4GLA
SCHEMBL4696277 0.79 MAOA (0.90) MAOAKDM4EALDH1A1CYP3A4GLA
Xanthone SCHEMBL41161 0.79 MAOA (1.00) MAOAKDM4EALDH1A1CYP3A4GLA
SCHEMBL3286115 0.78 MAOA (0.59) MAOAKDM4EALDH1A1CYP3A4GLA
SCHEMBL8117592 0.77 MAPT (0.39) MAOAKDM4EALDH1A1CYP3A4GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658081-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-05-24 EP claimed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 WO claimed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 US claimed
US-20240085784-A1 ORGANIC EL DISPLAY DEVICE TOYO INK SC HOLDINGS CO., LTD. (JP) 2024-03-14 US disclosed
US-20230104311-A1 NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-06 US disclosed
EP-4106763-A1 NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2022-12-28 EP disclosed
CN-109564384-B Photosensitive coloring composition and color filter 东洋油墨SC控股株式会社 2022-09-20 CN disclosed
EP-2864312-B1 NOVEL ANTI-CANCER THIOPHENE COMPOUNDS UNIV LEUVEN KATH (BE) 2021-09-22 EP disclosed
US-11124617-B2 Materials coated with calixarenes UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) 2021-09-21 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 WO disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 US disclosed
US-6479505-B1 TREATING AIRWAY DISORDER IN A PATIENT COMPRISING ADMINISTERING TO SAID PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PHOSPHODIESTERASE IV INHIBITOR ALTANA PHARMA AG (DE) 2002-11-12 US disclosed
EP-1147088-A1 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-10-24 EP disclosed
WO-2000042019-A1 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-07-20 WO disclosed
US-5116708-A HOLE TRANSPORTING MATERIAL NIPPON OIL COMPANY, LIMITED (JP) 1992-05-26 US disclosed
EP-0372979-A2 Hole transporting material NIPPON OIL COMPANY, LIMITED (JP) 1990-06-13 EP disclosed
US-4209638-A RESOLUTION OF ENANTIOMORPHS THE BOOTS COMPANY LIMITED (GB) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11124617-B2 Materials coated with calixarenes CALD1, CALU, CALR MAOA 1169/4885KDM4E 4423/4885ALDH1A1 1356/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 MAOA 2656/4885KDM4E 649/4885ALDH1A1 2743/4885
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives TPMT, NFATC1, MALT1 MAOA 1931/4885KDM4E 2108/4885ALDH1A1 1257/4885
US-20230104311-A1 NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS ADA, ADAR, TPMT MAOA 490/4885KDM4E 2019/4885ALDH1A1 444/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 MAOA 3201/4885KDM4E 1116/4885ALDH1A1 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.